Encapsia is a cloud-based clinical data suite developed by Cmed, a technology-led contract research organization (CRO). The platform is designed to streamline the capture, management, and reporting of clinical trial data, providing a unified database and user-centric applications for all trial processes. Encapsia supports flexible data collection through eSource, web EDC, home visits, wearables, and third-party labs, enabling real-time, actionable insights for sponsors, CROs, and sites.
Cmed was founded in 2000 in the UK, positioning itself as an innovative CRO focused on technology-driven solutions for complex clinical trials. Encapsia, as Cmed’s flagship platform, was launched to address industry gaps in data integration and real-time analytics. The platform has seen rapid adoption, with successful study completions and ongoing trials for several leading global pharmaceutical companies.
Cmed and encapsia have raised approximately $5 million in funding. Encapsia’s annual revenue reached $34 million in 2024, while Cmed Technology’s estimated annual revenue is over $105 million34.
eSource and web-based EDC for flexible data capture.
Home Visit app for remote and offline data entry.
Real-time data visualization and analytics.
Risk-based and remote monitoring.
Multi-media and third-party data integration.
Automated audit trails and compliance with regulatory standards (HIPAA, 21 CFR Part 11).
The acquisition of Cmed by Aixial Group in 2021 has accelerated encapsia’s development, enabling broader scaling and the addition of new features and apps. Encapsia now includes 12 powerful apps, expanding capabilities in risk-based monitoring, remote monitoring, and multi-media data capture.
Recent enhancements to encapsia include improved real-time visualizations, automated data loads, expanded offline capabilities for the Home Visit app, and greater integration with wearables and medical devices. The platform’s roadmap emphasizes supporting decentralized, hybrid, and traditional trials, with a focus on open access, customer-centric design, and adaptability to new IoT and digital health technologies.
Cmed and encapsia emphasize innovation, agility, and customer-centricity. The company culture is described as friendly and proactive, with a focus on collaboration, technical excellence, and responsiveness to customer needs.
Encapsia is used by a range of pharmaceutical and biotech companies, including several of the world’s top five pharma firms. Its user base includes clinical trial leads, data managers, biostatisticians, and site staff, as well as patients participating in decentralized trials. The platform’s community benefits from ongoing technical support, training, and engagement opportunities, with encapsia positioned as a forward-looking solution for organizations seeking to modernize clinical research operations.
